Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.51 |
| ▸ | MMP2 | P08253 | 4/20 | 0.50 |
| ▸ | MMP9 | P14780 | 3/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL626035 | 1.00 | MME (0.54) | MMENPSR1CYP1A2NAALAD2MMP2 | |
| SCHEMBL4880143 | 1.00 | MME (0.54) | MMENPSR1CYP1A2NAALAD2MMP2 | |
| SCHEMBL1081373 | 0.86 | FOLH1 (0.54) | MMENAALAD2ACEL3MBTL1FOLH1 | |
| SCHEMBL31533361 | 0.86 | FOLH1 (0.54) | MMENAALAD2ACEL3MBTL1FOLH1 | |
| SCHEMBL31533362 | 0.86 | FOLH1 (0.54) | MMENAALAD2ACEL3MBTL1FOLH1 | |
| SCHEMBL1081372 | 0.86 | FOLH1 (0.54) | MMENAALAD2ACEL3MBTL1FOLH1 | |
| SCHEMBL12207239 | 0.85 | MME (0.57) | MMENPSR1CYP1A2NAALAD2MMP2 | |
| SCHEMBL7596254 | 0.85 | MME (0.57) | MMENPSR1CYP1A2NAALAD2MMP2 | |
| SCHEMBL23925862 | 0.83 | MME (0.56) | MMENPSR1CYP1A2NAALAD2MMP2 | |
| SCHEMBL73955 | 0.83 | MME (0.56) | MMENPSR1CYP1A2NAALAD2MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-63148991-A | — | — | None | — | — | JP | disclosed |
| WO-2023164676-A1 | METHODS TO GENERATE NOVEL ACYL-TRNA SPECIES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-31 | — | — | WO | disclosed |
| CN-112533936-B | Method for purifying peptide using sulfonic acid compound | 长濑产业株式会社 | 2022-03-01 | — | — | CN | disclosed |
| CN-112533936-A | Method for purifying peptide using sulfonic acid compound | 长濑产业株式会社 | 2021-03-19 | — | — | CN | disclosed |
| CN-100581589-C | Radiolabeled amino acid analogs, their preparation and use | MALLINCKRODT INC | 2010-01-20 | — | — | CN | disclosed |
| US-20070081941-A1 | F-18 Labeled Amino Acid Analogs | MALLINCKRODT INC. (US) | 2007-04-12 | — | — | US | disclosed |
| US-7189383-B2 | Radioactively labelled amino acid analogues, their preparation and use | MALLINCKRODT INC. | 2007-03-13 | — | — | US | disclosed |
| US-20060127306-A1 | Radioactively labelled amino acid analogues, their preparation and use | VRIJE UNIVERSITEIT BRUSSEL (BE) | 2006-06-15 | — | — | US | disclosed |
| CN-1674943-A | Radiolabeled amino acid analogs, their preparation and use | MALLINCKRODT INC (US) | 2005-09-28 | — | — | CN | disclosed |
| EP-1539250-A1 | RADIOACTIVELY LABELLED AMINO ACID ANALOGUES, THEIR PREPARATION AND USE | Mallinckrodt Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004110500-A1 | RADIOACTIVELY LABELLED AMINO ACID ANALOGUES, THEIR PREPARATION AND USE | MALLINCKRODT INC. (US) | 2004-12-23 | — | — | WO | disclosed |
| JP-S63148991-A | PRODUCTION OF FLUOROMETHYL GROUP-CONTAINING PHENYLALANINE DERIVATIVE | ASAHI GLASS CO LTD | 1988-06-21 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070081941-A1 | F-18 Labeled Amino Acid Analogs | BCAT1, BCAT2, SLC1A5 | MME 1466/4885NPSR1 1051/4885CYP1A2 575/4885 |
| US-20060127306-A1 | Radioactively labelled amino acid analogues, their preparation and use | BCAT1, BCAT2, SLC1A5 | MME 2181/4885NPSR1 477/4885CYP1A2 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.